Marshall Wace North America’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Marshall Wace North America’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-39,890	Closed	-$139K	–	1836
2021 Q2	$139K	Buy	+39,890	New	+$137K	﹤0.01%	1374
2021 Q1	–	Sell	-11,140	Closed	-$214K	–	1889
2020 Q4	$214K	Buy	+11,140	New	+$172K	﹤0.01%	1220
2019 Q1	–	Sell	-8,284	Closed	-$117K	–	2025
2018 Q4	$117K	Buy	+8,284	New	+$129K	﹤0.01%	1054
2018 Q1	–	Sell	-18,897	Closed	-$472K	–	1797
2017 Q4	$472K	Buy	+18,897	New	+$446K	﹤0.01%	1154

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's ODT Position: Q3 2021 in Review

Marshall Wace North America sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 39,890 shares — an estimated $139K sold.

Marshall Wace North America first reported a position in ODT in Q4 2017 and held it in 4 quarters. The position peaked at $472K in Q4 2017. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

Marshall Wace North America reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 39,890 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $139K.
Marshall Wace North America first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
Marshall Wace North America's Odonate Therapeutics, Inc. Common Stock position peaked at $472K in Q4 2017.
58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.